Refractive Surgery

The LYNX-2 Phase 3 study is evaluating phentolamine ophthalmic solution 0.75% for the treatment of decreased visual acuity under low light conditions following keratorefractive surgery

The device is intended for use for LASIK vision correction surgery for myopia and myopic astigmatism.

According to the company, Phase 3 startup activities are underway, and the clinical trial is expected to start in the first quarter of 2024.

Procedure can reduce scleral biomechanical stiffness and rejuvenate dynamic range of focus.

Light-adjustable lens in patients with previous RK: Improved visual and refractive outcomes after cataract surgery.

Clear communication, transparent priceing, options are key to positive experience

Language can drive understanding, trust, and better outcomes for patients

New laser is designed to deliver low-energy treatment with ultrashort pulse duration.

Procedure offers sharp contrast to cutting procedures without risk, pain, or drama.

ICLs offer a strong surgical correction option for some patients.

In a presentation at the EnVision Summit 2023 in Puerto Rico, Sumayya Ahmad, MD, pointed out that for patients with lower Schirmer’s scores and corneal staining, PRK may be a good choice. If the dry eye can be treated preoperatively and the eye has no staining, surgeons can consider LASIK.

Physicians can use navigational tools to attain a much more immersive perspective.

Edward Hu, MD, PhD, looked at 812 toric IOLs utilized of various platforms, concluding a low total toric rotation rate at 2.1%.

The study assesses and compares the accuracy of IOL formulas using keratometry (K) and total keratometry (TK) values obtained by a swept-source OCT biometer (IOL Master 700) in eyes with previous PKP prior to cataract surgery.

Dr. Sri Ganesh, MBBS, MS, DNB, chairman and managing director of Nethradhama Hospital Pvt. Ltd, discusses his studies on LENSAR and shares his findings.

In a presentation at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting, Marjan Farid, MD, ABO, and Preeya K. Gupta, MD, offered details of clinical trials for CSF-1 ophthalmic solution, a presbyopia eye drop candidate. Results showed that nearly half of the participants treated with CSF-1 achieved a 3-line or more increase in the distance-corrected near visual acuity an hour after drop instillation on day 15.

Shervin Korangy, CEO of BVI, shares about the company's new technology, Beyeonics One, on display during ASCRS 2022.

This advancement reinforces Alcon’s commitment to surgeon training and education, as part of the Alcon Experience Academy. The new device will be introduced at the upcoming ASCRS meeting and surgeons will be able to experience the new technology firsthand.

Mark Packer, MD, shares his perspective on the relationship between ICL implantation or LASIK and retinal detachment.

Investigators examine usefulness in refractive surgery evaluations.

Early experience with next-generation lens engenders positive perception.

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

According to the Refractive Surgery Council, patients continue to have a high level of interest in laser vision correction procedures.

Colman R. Kraff, MD, shares highlights of a study evaluating the safety and efficacy of the use of the iDesign 2.0 Refractive Studio for the treatment of patients with hyperopia and myopia.

Investigators find little difference between the options.

In recognition of Cataract Awareness Month.

Procedure can improve best-corrected visual acuity, enhancing quality of life for patients.

Patients are serious about procedure and ready to move forward.

Investigators find treatment is an option for treating open-angle glaucoma.

Novel technique provides another option for normal and irregular corneas.